{"entity":{"id":"nct03441113","kind":"trial","name":"Extended Access of Momelotinib in Adults With Myelofibrosis","aka":[],"tldr":"A phase 2 trial of MMB in myeloproliferative neoplasms, run by GlaxoSmithKline, active and no longer recruiting.","summary":"Extended Access of Momelotinib in Adults With Myelofibrosis is a phase 2 interventional study registered as NCT03441113 by GlaxoSmithKline, with 237 participants enrolled, started 2018-05-03 and due to reach its primary completion in 2026-12-11. Interventions recorded: MMB.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03441113","url":"https://clinicaltrials.gov/study/NCT03441113"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms","primary-myelofibrosis"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03441113","phase":"2","setting":"Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)","sponsor":"GlaxoSmithKline","participation":[{"nct":"NCT03441113","source":"https://clinicaltrials.gov/study/NCT03441113","fetchedAt":"2026-10-07T16:53:02.192Z","studySha256":"8ac9edbbc8e9ce43eeb527f7abe74c3b06fa1f5c42e6777dede6bb47648e6ca9","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-06-18","leadSponsor":"GlaxoSmithKline","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":237,"enrolmentType":"ACTUAL","siteCount":112,"recruitingSiteCount":0,"countries":["Australia","Austria","Belgium","Bulgaria","Canada","Denmark","France","Germany","Hungary","Israel","Italy","Netherlands","Poland","Romania","Singapore","South Korea","Spain","Taiwan","United Kingdom","United States"]}],"started":"2018-05-03","startedType":"actual","enrolled":237,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03441113/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"},{"id":"primary-myelofibrosis","kind":"cancer","name":"Primary myelofibrosis","route":"/cancers/primary-myelofibrosis/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}